Funding-round
Parabilis Medicines - Series F
| Company | Parabilis Medicines |
|---|---|
| Amount | $305,000,000 |
| Currency | USD |
| Announcement date | 2026-01-08 |
| Round type | Series F |
| Primary source url | https://www.finsmes.com/2026/01/parabilis-medicines-raises-305m-series-f-funding.html |
| Terms or valuation | The company intends to use the funds for the continued clinical development of FOG-001 (zolucatetide) – its lead investigational Helicon peptide and direct inhibitor of the elusive β-catenin:TCF interaction – including progression toward a registrational trial in desmoid tumors and continued evaluation across a range of genetically simple and more complex tumor types |